Patients reported a significant physical burden associated with ATTR-CM; affecting ability to walk or to engage in social or household activities. Caregivers reported experiencing a mild to moderate ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier ...
BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Well, transthyretin cardiac amyloidosis is ...
According to a new study published in ESC Heart Failure, nearly 1 in 5 elderly patients with a permanent cardiac pacemaker and left ventricular hypertrophy (LVH) have transthyretin amyloid ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Unfortunately, the therapies that we have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results